<?xml version="1.0" encoding="UTF-8"?>
<xml>
 <records>
  <record>
   <ref-type name="Journal Article">17</ref-type>
   <contributors>
    <authors>
     <author>Bikbov, M.M.</author>
     <author>Kazakbaeva, G.M.</author>
     <author>Songhomitra Panda-Jonas</author>
     <author>Valishin, I.D.</author>
     <author>Nizamutdinova, A.M.</author>
     <author>Jost B. Jonas</author>
    </authors>
   </contributors>
   <titles>
    <title>Intravitreal panitumumab and retinal pigment epithelium proliferation in laser-induced retinal degeneration in rabbits</title>
   </titles>
   <keywords>
    <keyword>panitumumab</keyword>
    <keyword>epidermal growth factor receptor inhibitor</keyword>
    <keyword>macular degeneration</keyword>
    <keyword>retinal pigment epithelium</keyword>
    <keyword>macular scar</keyword>
    <keyword>intravitreal medication</keyword>
    <keyword>Scopus</keyword>
    <keyword>Web od Science</keyword>
   </keywords>
   <dates>
    <year>2025</year>
    <pub-dates>
     <date>2026-05-15</date>
    </pub-dates>
   </dates>
   <doi>10.3389/fopht.2025.1641194</doi>
   <journal>FRONTIERS IN OPHTHALMOLOGY</journal>
   <abstract>Purpose: This study aims to examine the effect of intravitreally applied epidermal&#13;
growth factor (EGF) receptor blocker panitumumab on the proliferation of retinal&#13;
pigment epithelium cells (RPE) in an experimental model of localized&#13;
retinal degeneration.&#13;
Methods: The experimental study included rabbits with age of 2 to 3 months and&#13;
body weight of 2.5–3 kg and which were randomly distributed into a study group&#13;
and control group. The right eyes received two retinal argon laser coagulation spots&#13;
(500 mW; diameter, 100 mm; duration, 0.5 s), applied with an interval of 2 min at the&#13;
same location close to the vascular streak in the posterior fundus region. For five&#13;
times at 2-day intervals, the rabbits of the study group received intravitreal injections&#13;
of 1 mg panitumumab (0.10 mL), and the rabbits of the control group had intravitreal&#13;
injections of 0.10 mL Ringer’s solution. At baseline, at each time point of reexamination, and at study end, the animals were examined by fundus&#13;
photography and optical coherence tomography of the laser spot.&#13;
Results: The study included 19 rabbits (study group: 10 animals; control group: nine&#13;
animals). After the third injection and at study end, the laser-induced area of&#13;
depigmentation + hyperpigmentation combined did not vary significantly between&#13;
the study group and the control group (1.43 ± 0.63 mm2 versus 1.63 ± 0.77 mm2&#13;
; P =&#13;
0.56; and 1.37 ± 0.63 mm2 versus 1.61 ± 0.74 mm2&#13;
; P = 0.46, respectively). At the&#13;
same time points, the area with hyperpigmentation was significantly smaller in the&#13;
study group than in the control group (0.16 ± 0.15 mm2 versus 0.80 ± 0.59 mm2&#13;
; P =&#13;
0.01; and 0.14 ± 0.14 mm2 versus 0.70 ± 0.56 mm2&#13;
; P = 0.02, respectively). At the&#13;
same time points, the ratio of the hyperpigmented area to the combined&#13;
depigmented + hyperpigmented area was significantly smaller in the study group&#13;
than in the control group (0.11 ± 0.09 versus 0.43 ± 0.19 mm2&#13;
; P &lt; 0.001; and 0.10 ±&#13;
0.08 versus 0.35 ± 0.23mm2&#13;
; P = 0.006, respectively). Conclusions: These findings indicate that intravitreally administered&#13;
panitumumab was associated with reduced subretinal hyperpigmentation in a&#13;
laser-induced model of retinal injury. While this may reflect a modulation of the&#13;
RPE response, including the potential suppression of RPE proliferation, further&#13;
studies incorporating histological and molecular analyses are warranted to&#13;
confirm its effect on subretinal fibrosis.</abstract>
   <urls>
    <web-urls>
     <url>https://repo.bashgmu.ru/publication/5326</url>
    </web-urls>
    <pdf-urls>
     <url>https://repo.bashgmu.ru/files/5518</url>
    </pdf-urls>
   </urls>
  </record>
 </records>
</xml>
